Genelabs Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Genelabs Technologies's estimated annual revenue is currently $4.5M per year.
- Genelabs Technologies's estimated revenue per employee is $155,000
Employee Data
- Genelabs Technologies has 29 Employees.
- Genelabs Technologies grew their employee count by -6% last year.
Genelabs Technologies's People
| Name | Title | Email/Phone |
|---|
Genelabs Technologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $9.1M | 59 | -9% | N/A | N/A |
#10 | $16.6M | 107 | 3% | N/A | N/A |
What Is Genelabs Technologies?
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
keywords:N/A
N/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 29 | 32% | $7M |
#2 | $7.5M | 29 | 0% | N/A |
#3 | $5M | 29 | 7% | N/A |
#4 | $2.9M | 29 | N/A | N/A |
#5 | $1.7M | 29 | N/A | N/A |